NDV-01 (sustained-release gemcitabine-docetaxel)

Phase 3Withdrawn

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)

Conditions

Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive), Bladder (Urothelial, Transitional Cell) Cancer, Urothelial Carcinoma Bladder, Urologic Cancer

Trial Timeline

May 1, 2026 → Nov 1, 2029

NCT ID

NCT07313891

About NDV-01 (sustained-release gemcitabine-docetaxel)

NDV-01 (sustained-release gemcitabine-docetaxel) is a phase 3 stage product being developed by Relmada Therapeutics for Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive). The current trial status is withdrawn. This product is registered under clinical trial identifier NCT07313891. Target conditions include Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive), Bladder (Urothelial, Transitional Cell) Cancer, Urothelial Carcinoma Bladder.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07342517	Phase 3	Withdrawn	Jun 30, 2026	Jun 30, 2028	Bladder (Urothelial, Transitional Cell) Cancer
NCT07464145	Phase 3	Recruiting	Jun 1, 2026	Sep 1, 2032	Bladder (Urothelial, Transitional Cell) Cancer
NCT07313891	Phase 3	Withdrawn	May 1, 2026	Nov 1, 2029	Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)

Competing Products

20 competing products in Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)

See all competitors

Product	Company	Stage	Hype Score
pegylated liposomal doxorubicin (PLD) + PD-1	CSPC Pharmaceutical Group Limited	Phase 2	51
EG-70 (phase 1) + EG-70 (phase 2)	enGene	Phase 1/2	33
mirabegron + solifenacin	Astellas Pharma	Approved	85
Trastuzumab deruxtecan	Daiichi Sankyo	Phase 2	52
Enfortumab vedotin	Astellas Pharma	Phase 1	33
Mirabegron + Placebo	Astellas Pharma	Approved	85
Solifenacin	Astellas Pharma	Approved	85
Mirabegron + Tolterodine + Placebo to Mirabegron + Placebo to Tolterodine	Astellas Pharma	Phase 3	77
solifenacin succinate	Astellas Pharma	Phase 3	77
Solifenacin	Astellas Pharma	Pre-clinical	23
Betanis	Astellas Pharma	Pre-clinical	23
Solifenacin	Astellas Pharma	Approved	85
Solifenacin	Astellas Pharma	Phase 2	52
Mirabegron + Tolterodine ER	Astellas Pharma	Approved	85
mirabegron + solifenacin + darifenacin + imidafenacin + tolterodine + oxybutynin + trospium + fesoterodine + propiverine	Astellas Pharma	Pre-clinical	23
Enfortumab vedotin + Pembrolizumab	Astellas Pharma	Phase 2	52
MK-3475 + ASG-22CE	Astellas Pharma	Phase 2	52
Enfortumab Vedotin + Pembrolizumab	Astellas Pharma	Phase 2	52
Alpha blocker + placebo + solifenacin	Astellas Pharma	Approved	85
warfarin + YM178	Astellas Pharma	Phase 1	33

Other Products from Relmada Therapeutics

REL-1017 + PlaceboPhase 3

NDV-01 (sustained-release gemcitabine-docetaxel)Phase 3

REL-1017Phase 3